Crescent Biopharma, Inc.
CBIO
$17.14
$0.513.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -165.12M | -162.08M | -153.94M | -- | -- |
| Total Depreciation and Amortization | 212.00K | 148.00K | 84.00K | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 93.43M | 98.68M | 95.70M | -- | -- |
| Change in Net Operating Assets | -1.19M | -6.37M | -13.37M | -- | -- |
| Cash from Operations | -72.68M | -69.62M | -71.53M | -- | -- |
| Capital Expenditure | -939.00K | -1.07M | -919.00K | -- | -- |
| Sale of Property, Plant, and Equipment | 1.77M | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -80.00M | -80.00M | -72.00M | -- | -- |
| Cash from Investing | -79.17M | -81.07M | -72.92M | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 179.14M | 323.14M | 323.15M | -- | -- |
| Repurchase of Common Stock | -1.25M | -1.43M | -1.43M | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.09M | -4.19M | 1.27M | -- | -- |
| Cash from Financing | 170.80M | 317.53M | 322.98M | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.95M | 166.84M | 178.53M | -- | -- |